RemeGen Co., Ltd. (HKG:9995)
Hong Kong · Delayed Price · Currency is HKD 70.50
-1.90 (-2.62%)
Jun 5, 2026, 4:09 PM HKT
RemeGen Employees
RemeGen had 3,048 employees as of December 31, 2025. The number of employees increased by 49 or 1.63% compared to the previous year.
Employees
3,048
Change (1Y)
49
Growth (1Y)
1.63%
Revenue / Employee
1.26M HKD
Profits / Employee
481.74K HKD
Market Cap
56.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,048 | 49 | 1.63% |
| Dec 31, 2024 | 2,999 | -616 | -17.04% |
| Dec 31, 2023 | 3,615 | 283 | 8.49% |
| Dec 31, 2022 | 3,332 | 1,211 | 57.10% |
| Dec 31, 2021 | 2,121 | 755 | 55.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| Innovent Biologics | 7,502 |
| Genscript Biotech | 6,165 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| Akeso | 3,761 |
| Shanghai Junshi Biosciences | 2,903 |
RemeGen News
- 5 weeks ago - RemeGen Earnings release: Q1 2026 - Filings
- 5 weeks ago - RemeGen Annual report: Q4 2025 - Filings
- 5 weeks ago - RemeGen Slides: Q4 2025 - Filings
- 5 months ago - AbbVie, RemeGen partner on experimental solid tumor treatment - Reuters
- 7 months ago - RemeGen Earnings release: Q3 2025 - Filings
- 7 months ago - RemeGen Slides: Q3 2025 - Filings
- 8 months ago - 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China - PRNewsWire
- 9 months ago - RemeGen Quarterly report: Q2 2025 - Filings